Weight & metabolic
AOD-9604
Anti-Obesity Drug Fragment
A modified fragment of human growth hormone (HGH) that retains the fat-burning properties without the growth-promoting or blood sugar effects.
Also known as: AOD9604, HGH Fragment 176-191
- Status
- AOD-9604 is a research compound and not approved by the FDA for human use.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- ~4-6 hours
- How it's taken
- Subcutaneous injection
- Mechanism
- Metabolic (non-incretin)
How AOD-9604 works
Mimics the way natural growth hormone breaks down fat (lipolysis) by targeting fat cells directly. Unlike full HGH, it doesn't affect insulin or blood sugar levels, making it a more targeted approach.
What research has looked at
- Targeted fat reduction
- No impact on blood sugar or insulin
- No growth-promoting effects
- May support cartilage repair
- Relatively mild side effect profile
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Injection site reactions
- Mild headache
- Indigestion
- Generally well-tolerated in trials
- Not FDA-approved for weight loss
Sources
- PubMed research on AOD-9604 growth hormone fragment lipolysis · NIH · National Library of Medicine
- Active clinical trials for AOD-9604 · U.S. National Library of Medicine
- DrugBank record for AOD-9604 · DrugBank
Track AOD-9604 in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
AOD-9604 FAQ
What is AOD-9604?
A modified fragment of human growth hormone (HGH) that retains the fat-burning properties without the growth-promoting or blood sugar effects.
How does AOD-9604 work?
Mimics the way natural growth hormone breaks down fat (lipolysis) by targeting fat cells directly. Unlike full HGH, it doesn't affect insulin or blood sugar levels, making it a more targeted approach.
Is AOD-9604 FDA approved?
No. AOD-9604 is a research compound and not approved by the FDA for human use. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of AOD-9604?
Reported half-life: ~4-6 hours.
How is AOD-9604 taken?
Subcutaneous injection.
What side effects have been reported with AOD-9604?
Reported in the sources: Injection site reactions; Mild headache; Indigestion; Generally well-tolerated in trials; Not FDA-approved for weight loss.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.